vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and Eightco Holdings Inc. (ORBS). Click either name above to swap in a different company.
CytomX Therapeutics, Inc. is the larger business by last-quarter revenue ($18.7M vs $10.2M, roughly 1.8× Eightco Holdings Inc.). CytomX Therapeutics, Inc. runs the higher net margin — -0.8% vs -2281.6%, a 2280.8% gap on every dollar of revenue. On growth, CytomX Therapeutics, Inc. posted the faster year-over-year revenue change (-25.7% vs -49.9%). Eightco Holdings Inc. produced more free cash flow last quarter ($-11.0M vs $-15.8M). Over the past eight quarters, Eightco Holdings Inc.'s revenue compounded faster (13.1% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
CTMX vs ORBS — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $10.2M |
| Net Profit | $-154.0K | $-232.5M |
| Gross Margin | — | -13.0% |
| Operating Margin | -6.9% | -475.0% |
| Net Margin | -0.8% | -2281.6% |
| Revenue YoY | -25.7% | -49.9% |
| Net Profit YoY | 97.6% | -9183.3% |
| EPS (diluted) | — | $-2.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $10.2M | ||
| Q3 25 | — | $5.3M | ||
| Q2 25 | $18.7M | $7.6M | ||
| Q1 25 | $50.9M | $9.9M | ||
| Q4 24 | $38.1M | $20.3M | ||
| Q3 24 | $33.4M | $6.1M | ||
| Q2 24 | $25.1M | $5.3M | ||
| Q1 24 | $41.5M | $8.0M |
| Q4 25 | — | $-232.5M | ||
| Q3 25 | — | $-25.8M | ||
| Q2 25 | $-154.0K | $-1.2M | ||
| Q1 25 | $23.5M | $-2.5M | ||
| Q4 24 | $18.9M | $-2.5M | ||
| Q3 24 | $5.7M | $-3.2M | ||
| Q2 24 | $-6.5M | $4.4M | ||
| Q1 24 | $13.8M | $1.9M |
| Q4 25 | — | -13.0% | ||
| Q3 25 | — | -3.7% | ||
| Q2 25 | — | 16.4% | ||
| Q1 25 | — | 8.2% | ||
| Q4 24 | — | 8.2% | ||
| Q3 24 | — | 26.5% | ||
| Q2 24 | — | 25.1% | ||
| Q1 24 | — | 17.5% |
| Q4 25 | — | -475.0% | ||
| Q3 25 | — | -116.9% | ||
| Q2 25 | -6.9% | -15.9% | ||
| Q1 25 | 44.4% | -14.3% | ||
| Q4 24 | 46.4% | -11.9% | ||
| Q3 24 | 12.3% | -29.1% | ||
| Q2 24 | -33.7% | -16.4% | ||
| Q1 24 | 28.1% | -39.6% |
| Q4 25 | — | -2281.6% | ||
| Q3 25 | — | -487.6% | ||
| Q2 25 | -0.8% | -15.4% | ||
| Q1 25 | 46.2% | -25.7% | ||
| Q4 24 | 49.6% | -12.3% | ||
| Q3 24 | 17.2% | -52.5% | ||
| Q2 24 | -26.0% | 84.2% | ||
| Q1 24 | 33.3% | 24.4% |
| Q4 25 | — | $-2.34 | ||
| Q3 25 | — | $-0.58 | ||
| Q2 25 | — | $-0.38 | ||
| Q1 25 | — | $-0.84 | ||
| Q4 24 | — | $-1.44 | ||
| Q3 24 | — | $-1.77 | ||
| Q2 24 | — | $2.15 | ||
| Q1 24 | — | $1.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $58.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $232.6M |
| Total Assets | $175.1M | $250.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $58.5M | ||
| Q3 25 | — | $23.7M | ||
| Q2 25 | $49.0M | $696.3K | ||
| Q1 25 | $47.6M | $434.4K | ||
| Q4 24 | $38.1M | $239.2K | ||
| Q3 24 | $40.6M | $2.4M | ||
| Q2 24 | $43.2M | $363.1K | ||
| Q1 24 | $36.2M | $808.8K |
| Q4 25 | — | $232.6M | ||
| Q3 25 | — | $339.2M | ||
| Q2 25 | $119.9M | $8.9M | ||
| Q1 25 | $25.0M | $9.7M | ||
| Q4 24 | $-456.0K | $11.9M | ||
| Q3 24 | $-23.5M | $13.0M | ||
| Q2 24 | $-31.2M | $13.8M | ||
| Q1 24 | $-31.7M | $3.9M |
| Q4 25 | — | $250.2M | ||
| Q3 25 | — | $355.5M | ||
| Q2 25 | $175.1M | $48.7M | ||
| Q1 25 | $98.5M | $47.6M | ||
| Q4 24 | $120.5M | $50.8M | ||
| Q3 24 | $139.0M | $49.2M | ||
| Q2 24 | $159.2M | $48.4M | ||
| Q1 24 | $184.7M | $50.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $-11.0M |
| Free Cash FlowOCF − Capex | $-15.8M | $-11.0M |
| FCF MarginFCF / Revenue | -84.6% | -107.7% |
| Capex IntensityCapex / Revenue | 0.1% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-11.0M | ||
| Q3 25 | — | $-1.6M | ||
| Q2 25 | $-15.8M | $-659.2K | ||
| Q1 25 | $-21.0M | $999.8K | ||
| Q4 24 | $-19.9M | $-6.6M | ||
| Q3 24 | $-20.7M | $77.7K | ||
| Q2 24 | $-19.5M | $-440.3K | ||
| Q1 24 | $-26.0M | $-723.3K |
| Q4 25 | — | $-11.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | $-15.8M | $-661.3K | ||
| Q1 25 | $-21.2M | $999.7K | ||
| Q4 24 | $-20.0M | $-6.6M | ||
| Q3 24 | $-20.7M | $73.0K | ||
| Q2 24 | $-19.6M | — | ||
| Q1 24 | $-26.2M | — |
| Q4 25 | — | -107.7% | ||
| Q3 25 | — | — | ||
| Q2 25 | -84.6% | -8.7% | ||
| Q1 25 | -41.6% | 10.1% | ||
| Q4 24 | -52.5% | -32.7% | ||
| Q3 24 | -62.1% | 1.2% | ||
| Q2 24 | -78.2% | — | ||
| Q1 24 | -63.1% | — |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | 0.1% | 0.0% | ||
| Q1 25 | 0.2% | 0.0% | ||
| Q4 24 | 0.2% | 0.0% | ||
| Q3 24 | 0.1% | 0.1% | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 0.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | -0.10× | ||
| Q1 24 | -1.89× | -0.37× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
ORBS
Segment breakdown not available.
